A new class of treatment that can selectively destroy cancer cells using a light-activated viral nanoparticle has received FDA fast track designation for the treatment of ocular melanoma.
Publications
Publications for March 2017
Interleukin 10 decreases MICA expression on melanoma cell surface
FDA grants fast track designation to ImmunoPulse IL-12 for melanoma
The FDA granted fast track designation to ImmunoPulse IL-12 for the treatment of metastatic melanoma that progressed during therapy with pembrolizumab or nivolumab.
Melanoma Journal Articles for February 2017
Risk of cumulative toxicity after complete melanoma response with pembrolizumab.